Compare Victoria's Secret & Co (VSXY) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Victoria's Secret & Co vs Zimmer Biomet Holdings Inc — how do they compare? Victoria's Secret & Co trades at $82.86 (market cap $6.91B), while Zimmer Biomet Holdings Inc trades at $89.91 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.5× Victoria's Secret & Co's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Victoria's Secret & Co pays none. Which is the better fit depends on your goals — on Pluang, investors hold Victoria's Secret & Co for 34 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| VSXY | ZBH | |
|---|---|---|
Market Cap | $6.91B | $16.95B |
Volume | 1,346,928 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $99.97 | $103.98 |
52-Week Low | $28.25 | $79.58 |
Typical Hold Time | 34 Days | 89 Days |
Enterprise Value | $9.29B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Victoria's Secret (VSXY) trades at $82.87, down 3.4% on the day, but maintains strong analyst support with a 60% buy rating and $86.80 consensus price target. The stock shows bullish technical momentum with recent earnings beats in Q4 2025 and Q1-Q2 2026, while fundamentals reveal improving profitability with 39.57% gross margins and 45.27% ROE. Recent news highlights brand momentum through fashion show expansions and omnichannel retail growth.
The outlook remains positive with projected 2026 revenue growth to $6.9B and net income of $378M, though risks include elevated valuation metrics (P/E 19.33) and competitive pressures. Institutional interest is strengthening with recent investments from Tidal Investments and California State Teachers Retirement System, supporting the bullish case for long-term investors.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
